Gain Therapeutics Statistics
Total Valuation
GANX has a market cap or net worth of $78.15 million. The enterprise value is $61.21 million.
Important Dates
The next estimated earnings date is Wednesday, May 13, 2026, before market open.
| Earnings Date | May 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GANX has 42.24 million shares outstanding. The number of shares has increased by 44.08% in one year.
| Current Share Class | 42.24M |
| Shares Outstanding | 42.24M |
| Shares Change (YoY) | +44.08% |
| Shares Change (QoQ) | +8.06% |
| Owned by Insiders (%) | 3.17% |
| Owned by Institutions (%) | 19.45% |
| Float | 40.90M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.42 |
| P/TBV Ratio | 4.40 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.63, with a Debt / Equity ratio of 0.04.
| Current Ratio | 6.63 |
| Quick Ratio | 6.46 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -155.66% and return on invested capital (ROIC) is -85.80%.
| Return on Equity (ROE) | -155.66% |
| Return on Assets (ROA) | -67.01% |
| Return on Invested Capital (ROIC) | -85.80% |
| Return on Capital Employed (ROCE) | -96.22% |
| Weighted Average Cost of Capital (WACC) | 4.82% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$960,052 |
| Employee Count | 21 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, GANX has paid $861,118 in taxes.
| Income Tax | 861,118 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -1.32% in the last 52 weeks. The beta is 0.11, so GANX's price volatility has been lower than the market average.
| Beta (5Y) | 0.11 |
| 52-Week Price Change | -1.32% |
| 50-Day Moving Average | 2.16 |
| 200-Day Moving Average | 2.18 |
| Relative Strength Index (RSI) | 43.21 |
| Average Volume (20 Days) | 533,927 |
Short Selling Information
The latest short interest is 3.33 million, so 7.89% of the outstanding shares have been sold short.
| Short Interest | 3.33M |
| Short Previous Month | 3.28M |
| Short % of Shares Out | 7.89% |
| Short % of Float | 8.14% |
| Short Ratio (days to cover) | 4.68 |
Income Statement
| Revenue | n/a |
| Gross Profit | -10.07M |
| Operating Income | -18.73M |
| Pretax Income | -19.30M |
| Net Income | -20.16M |
| EBITDA | -18.69M |
| EBIT | -18.73M |
| Earnings Per Share (EPS) | -$0.61 |
Full Income StatementBalance Sheet
The company has $20.84 million in cash and $732,067 in debt, giving a net cash position of $20.11 million or $0.48 per share.
| Cash & Cash Equivalents | 20.84M |
| Total Debt | 732,067 |
| Net Cash | 20.11M |
| Net Cash Per Share | $0.48 |
| Equity (Book Value) | 18.56M |
| Book Value Per Share | 0.44 |
| Working Capital | 18.88M |
Full Balance SheetCash Flow
| Operating Cash Flow | -18.47M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 45,046 |
| Net Borrowing | -96,501 |
| Free Cash Flow | -18.47M |
| FCF Per Share | -$0.44 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |